Clinical trials
Completed Heart Failure trials in Brazil
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
78 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 5 |
| 2009 | 6 |
| 2010 | 4 |
| 2011 | 6 |
| 2012 | 4 |
| 2013 | 8 |
| 2014 | 7 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 8 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 78 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Sao Paulo | 10 |
| University of Sao Paulo General Hospital | 9 |
| Hospital de Clinicas de Porto Alegre | 5 |
| Instituto de Cardiologia do Rio Grande do Sul | 5 |
| Novartis Pharmaceuticals | 5 |
| Universidade Federal de Pernambuco | 4 |
| AstraZeneca | 2 |
| Boehringer Ingelheim | 2 |
| Federal University of São Paulo | 2 |
| Federal University of Uberlandia | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Heart Failure | 78 |
| Cardiovascular Diseases | 5 |
| Heart Failure, Diastolic | 4 |
| Atrial Fibrillation | 3 |
| Cardiomyopathies | 3 |
| Cardiomyopathy, Dilated | 3 |
| Chagas Disease | 3 |
| Coronary Artery Disease | 3 |
| Stroke | 3 |
| Aneurysm | 2 |
Trials
Showing 1 to 25 of 78. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.